Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| percent response | BAO_0000082 | [Percent increase or decrease of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay.] |
| EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | CHEBI_68640 | |
| EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor | CHEBI_76840 | |
| coupled enzyme activity measurement method | BAO_0000142 | [This technology is used to measure the effect of a perturbagen on an enzyme activity, which is coupled to a secondary signal. E.g., the activity of a kinase determines the residual pool of ATP, with ATP being its substrate, which in turn determines the rate of a coupled enzyme luciferase, since ATP is one of its substrates too.] |
| vulval Paget's disease | DOID_2097 | |
| vulva adenocarcinoma | DOID_2098 | [A vulva carcinoma that derives_from epithelial cells of glandular origin.] |
| Luciferin 4-monooxygenase | BAO_0000141 | [An oxidative enzyme that catalyzes the conversion of luciferin to oxyluciferin with the concomitant emission of light (luminescence).] |
| oxidoreductase | BAO_0000291 | [To catalyze oxidation/reduction reactions; transfer of H and O atoms or electrons from one substance to another.] |
| vulva carcinoma | DOID_1294 | [A vulva cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.] |
| inversely correlated | BAO_0000140 | |
| antidiarrhoeal drug | CHEBI_55323 | |
| gastrointestinal drug | CHEBI_55324 | |
| mu-opioid receptor agonist | CHEBI_55322 | |
| opioid receptor agonist | CHEBI_60606 | |
| mu-opioid agent | CHEBI_60599 | |
| nuclear magnetic resonance | BAO_0000160 | [Nuclear magnetic resonance (NMR) is used to analyze protein-small molecule interactions. This binding interaction is commonly monitored by the chemical shift of the compound. With this technique, both the binding interaction and bound compounds can be detected, which allows pools of 5-100 compounds to be tested for binding.] |
| positive allosteric modulation | BAO_0001491 | |
| allosteric modulation | BAO_0000489 | [An allosteric effector operates to enhance active site substrate affinity and/or catalysis. An allosteric inhibitor decreases activity by binding to an allosteric site, other than or in addition to the active site on the target. This interaction is characterized by a conformational change in the target enzyme that is required for inhibition.] |
| negative allosteric modulation | BAO_0001490 | |
| Scheuermann's disease | DOID_13300 | [An osteochondrosis that results_in abnormal bone growth and curvature located_in thoracic vertebral column.] |